Dyslipidemias
|
0.310 |
Biomarker
|
group |
BEFREE |
Insights into the interaction of PLTP with lipoproteins at the molecular level provide a basis to understand the PLTP-dependent lipid transfer mechanisms for dyslipidemia treatment.
|
29883800 |
2018 |
Dyslipidemias
|
0.310 |
Biomarker
|
group |
CTD_human |
Common single-nucleotide polymorphisms act in concert to affect plasma levels of high-density lipoprotein cholesterol.
|
17952847 |
2007 |
Hypertriglyceridemia
|
0.310 |
AlteredExpression
|
phenotype |
LHGDN |
Associations between CET, lipids, insulin resistance, CETP and PLTP activities, and PLTP mass were investigated in 18 HTG patients and 20 controls.
|
12754275 |
2003 |
Hypertriglyceridemia
|
0.310 |
Biomarker
|
phenotype |
CTD_human |
Associations between CET, lipids, insulin resistance, CETP and PLTP activities, and PLTP mass were investigated in 18 HTG patients and 20 controls.
|
12754275 |
2003 |
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
Dyslipoproteinemias
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Common single-nucleotide polymorphisms act in concert to affect plasma levels of high-density lipoprotein cholesterol.
|
17952847 |
2007 |
Insulin Resistance
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Regression analysis showed a positive contribution of PLTP mass (P = 0.001) but not of PLTP activity to HDL cholesterol, whereas insulin resistance positively contributed to PLTP activity (P < 0.01).
|
12754275 |
2003 |
Insulin Sensitivity
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy.
|
12754275 |
2003 |
Dry Eye Syndromes
|
0.200 |
Biomarker
|
disease |
MGD |
|
|
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phospholipid transfer protein (PLTP) is one of the key regulators of lipoprotein metabolism; PLTP-deficient mice exhibit decreased apolipoprotein B (apoB)-containing lipoprotein secretion and atherosclerosis, indicating the validity of PLTP as a promising therapeutic target.
|
31017809 |
2019 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phospholipid transfer protein (PLTP) is one of the key regulators of lipoprotein metabolism; PLTP-deficient mice exhibit decreased apolipoprotein B (apoB)-containing lipoprotein secretion and atherosclerosis, indicating the validity of PLTP as a promising therapeutic target.
|
31017809 |
2019 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phospholipid transfer protein (PLTP) is one of the major modulators of lipoprotein metabolism and atherosclerosis development; however, little is known about the regulation of PLTP.
|
29680823 |
2018 |
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this review, I summarize the major progress made in the PLTP research field and emphasize its impact on lipoprotein metabolism and atherosclerosis, as well as its regulation.
|
29438986 |
2018 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition to its role in lipoprotein metabolism and atherosclerosis, the latest advances came in support of a complex role of PLTP in the regulation of the inflammatory response, both with pro-inflammatory or anti-inflammatory properties.
|
29565987 |
2018 |
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this review, I summarize the major progress made in the PLTP research field and emphasize its impact on lipoprotein metabolism and atherosclerosis, as well as its regulation.
|
29438986 |
2018 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition to its role in lipoprotein metabolism and atherosclerosis, the latest advances came in support of a complex role of PLTP in the regulation of the inflammatory response, both with pro-inflammatory or anti-inflammatory properties.
|
29565987 |
2018 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phospholipid transfer protein (PLTP) is one of the major modulators of lipoprotein metabolism and atherosclerosis development; however, little is known about the regulation of PLTP.
|
29680823 |
2018 |
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, validating this hypothesis may clarify the role of PLTP in macrophage ERs in AS and also raise a novel strategy in the regression of AS plaques via restoring intracellular membrane lipid homeostasis and attenuating ERs.
|
28012603 |
2017 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although plasma phospholipid transfer protein (PLTP) has been mainly studied in the context of atherosclerosis, it shares homology with proteins involved in innate immunity.
|
28596518 |
2017 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, validating this hypothesis may clarify the role of PLTP in macrophage ERs in AS and also raise a novel strategy in the regression of AS plaques via restoring intracellular membrane lipid homeostasis and attenuating ERs.
|
28012603 |
2017 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although plasma phospholipid transfer protein (PLTP) has been mainly studied in the context of atherosclerosis, it shares homology with proteins involved in innate immunity.
|
28596518 |
2017 |
High density lipoprotein measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Exploration of haplotype research consortium imputation for genome-wide association studies in 20,032 Generation Scotland participants.
|
28270201 |
2017 |
Gambling, Pathological
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study of pathological gambling.
|
27315593 |
2016 |
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Importantly, p53 augmented the activity of secreted PLTP, which plays a major role in lipoprotein biology and atherosclerosis pathology.
|
22037227 |
2012 |